痴呆的生物标志物。
Biomarkers of the dementia.
作者信息
Shoji Mikio
机构信息
Department of Neurology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8216, Japan.
出版信息
Int J Alzheimers Dis. 2011;2011:564321. doi: 10.4061/2011/564321. Epub 2011 May 30.
Abstract
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, and phosphorylated tau are the most sensitive biomarkers for diagnosis of Alzheimer's disease (AD) and prediction of onset of AD from mild cognitive impairment (MCI). Based on this progress, new diagnostic criteria for AD, MCI, and preclinical AD were proposed by National Institute of Aging (NIA) and Alzheimer's Association in August 2010. In these new criteria, progress in biomarker identification and amyloid imaging studies in the past 10 years have added critical information. Huge contributions of basic and clinical studies have established clinical evidence supporting these markers. Based on this progress, essential therapy for cure of AD is urgently expected.
摘要
本文总结了痴呆生物标志物研究的最新进展。脑脊液Aβ40、Aβ42、总tau蛋白和磷酸化tau蛋白是诊断阿尔茨海默病（AD）以及预测从轻度认知障碍（MCI）发展为AD的最敏感生物标志物。基于这一进展，美国国立衰老研究所（NIA）和阿尔茨海默病协会于2010年8月提出了AD、MCI和临床前AD的新诊断标准。在这些新标准中，过去10年生物标志物鉴定和淀粉样蛋白成像研究的进展增添了关键信息。基础研究和临床研究的巨大贡献确立了支持这些标志物的临床证据。基于这一进展，人们迫切期待能找到治愈AD的根本疗法。
相似文献
1
Biomarkers of the dementia.痴呆的生物标志物。
Int J Alzheimers Dis. 2011;2011:564321. doi: 10.4061/2011/564321. Epub 2011 May 30.
2
[Biomarker of dementia: clinical and preclinical diagnosis].[痴呆症的生物标志物：临床与临床前诊断]
Nihon Rinsho. 2012 May;70(5):857-63.
3
Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease.阿尔茨海默病的治疗、预防和诊断的分子方法：阿尔茨海默病的临床分子和遗传学研究。
J Pharmacol Sci. 2012;118(3):345-9. doi: 10.1254/jphs.11r13fm. Epub 2012 Mar 2.
4
Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.脑脊液 Aβ42 和 Tau 测量在早期发病痴呆轻度认知障碍诊断中的临床效用。
J Alzheimers Dis. 2022;87(2):771-780. doi: 10.3233/JAD-215650.
5
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.阿尔茨海默病的核心候选神经化学和成像生物标志物。
Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21.
6
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.生物标志物组合对预测轻度认知障碍向阿尔茨海默病痴呆进展的增量价值。
Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.
7
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.NIA-AA 研究框架的应用：在 AIBL 研究中使用脑脊液生物标志物来定义阿尔茨海默病的生物学定义。
J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25.
8
[Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].[阿尔茨海默病的生物标志物：阿尔茨海默病神经影像学计划研究之后]
Brain Nerve. 2012 May;64(5):497-504.
9
Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.神经退行性疾病中的脑脊液和血浆生物标志物。
J Alzheimers Dis. 2019;68(1):395-404. doi: 10.3233/JAD-181152.
10
[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].[美国国立衰老研究所和阿尔茨海默病协会关于阿尔茨海默病诊断指南的2011年新建议：临床前阶段、轻度认知障碍和痴呆症]
Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12.
引用本文的文献
1
Voice biomarkers as indicators of cognitive changes in middle and later adulthood.嗓音生物标志物可作为中年后期认知变化的指标。
Neurobiol Aging. 2022 Nov;119:22-35. doi: 10.1016/j.neurobiolaging.2022.06.010. Epub 2022 Jul 1.
2
Minocycline attenuates post-operative cognitive impairment in aged mice by inhibiting microglia activation.米诺环素通过抑制小胶质细胞活化减轻老年小鼠术后认知功能障碍。
J Cell Mol Med. 2016 Sep;20(9):1632-9. doi: 10.1111/jcmm.12854. Epub 2016 Apr 6.
3
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.载脂蛋白 E/淀粉样蛋白-β（Aβ）复合物的可溶性水平降低，寡聚体 Aβ 增加与 APOE4 和阿尔茨海默病在转基因小鼠模型和人类样本中。
J Biol Chem. 2013 Feb 22;288(8):5914-26. doi: 10.1074/jbc.M112.442103. Epub 2013 Jan 4.
4
Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study.血浆淀粉样蛋白-β水平与 3 城市研究中首发痴呆病例的预后。
J Alzheimers Dis. 2013;33(2):381-91. doi: 10.3233/JAD-2012-121147.
5
Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.肌定向抗 Aβ 单链抗体通过 AAV1 递送至阿尔茨海默病小鼠模型中，降低脑 Aβ 负荷。
J Mol Neurosci. 2013 Feb;49(2):277-88. doi: 10.1007/s12031-012-9877-3. Epub 2012 Sep 4.
本文引用的文献
1
Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.脑脊液β淀粉样蛋白40和β淀粉样蛋白42：自然病程及临床应用价值
J Alzheimers Dis. 2001 Jan 1;3(3):313-21.
2
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.痴呆症谱系中脑脊液异常与日常功能衰退率：正常衰老、轻度认知障碍和阿尔茨海默病
Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.
3
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.基于正常老年人脑脊液和磁共振成像标志物的亚型可预测认知能力下降。
Neurobiol Aging. 2010 Aug;31(8):1419-28. doi: 10.1016/j.neurobiolaging.2010.04.025. Epub 2010 Jun 9.
4
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.ADNI 受试者中 3D-PIB 和 CSF 生物标志物与海马萎缩的相关性。
Neurobiol Aging. 2010 Aug;31(8):1284-303. doi: 10.1016/j.neurobiolaging.2010.05.003. Epub 2010 Jun 11.
5
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.阿尔茨海默病神经影像学倡议受试者的生物标志物核心更新。
Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008.
6
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.DJ-1 和α-突触核蛋白在人脑脊液中作为帕金森病的生物标志物。
Brain. 2010 Mar;133(Pt 3):713-26. doi: 10.1093/brain/awq008. Epub 2010 Feb 15.
7
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.阿尔茨海默病神经影像学倡议（ADNI）：临床特征。
Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.
8
Ten-year change in plasma amyloid beta levels and late-life cognitive decline.血浆β淀粉样蛋白水平的十年变化与晚年认知能力下降
Arch Neurol. 2009 Oct;66(10):1247-53. doi: 10.1001/archneurol.2009.207.
9
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.淀粉样蛋白β的动态变化受食欲素和睡眠-觉醒周期的调节。
Science. 2009 Nov 13;326(5955):1005-7. doi: 10.1126/science.1180962. Epub 2009 Sep 24.
10
Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.血浆β淀粉样蛋白与痴呆风险的关联：前瞻性三城市研究
Neurology. 2009 Sep 15;73(11):847-53. doi: 10.1212/WNL.0b013e3181b78448.
Zotero 插件